Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report) saw a significant growth in short interest in November. As of November 15th, there was short interest totalling 4,300 shares, a growth of 38.7% from the October 31st total of 3,100 shares. Based on an average daily trading volume, of 16,100 shares, the short-interest ratio is presently 0.3 days.
Adlai Nortye Stock Performance
Shares of ANL traded up $0.02 on Friday, hitting $2.23. 1,954 shares of the stock traded hands, compared to its average volume of 11,709. Adlai Nortye has a 1 year low of $1.85 and a 1 year high of $17.48. The stock’s 50 day moving average is $2.27 and its two-hundred day moving average is $3.76.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Adlai Nortye in a research report on Monday, November 11th.
Adlai Nortye Company Profile
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Read More
- Five stocks we like better than Adlai Nortye
- With Risk Tolerance, One Size Does Not Fit All
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- How to Plot Fibonacci Price Inflection Levels
- 3 Penny Stocks Ready to Break Out in 2025
- What Does Downgrade Mean in Investing?
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
